Compare Skyworks Solutions Inc (SWKS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Skyworks Solutions Inc trades at $76.8 (market cap $18.01B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Skyworks Solutions Inc is far larger — about 2.4× Spyre Therapeutics Inc. Common Stock's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Skyworks Solutions Inc for 50 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SWKS | SYRE | |
|---|---|---|
Market Cap | $18.01B | $7.52B |
Volume | 4,074,606 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $91.45 | $108.92 |
52-Week Low | $52.50 | $22.18 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $17.89B | $6.52B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $76.89, up 2.93% with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.10M. The pending Qorvo merger dominates news coverage, with analysts projecting significant synergies. Current valuation metrics include a P/E of 39.68 and P/S of 2.87, while cash flow trends show recent negative net cash flow of -$207.30M.
The investment outlook balances merger synergies against fundamental deterioration. Analyst consensus favors Buy (60%) with a $79.70 price target, but declining profitability and bearish technicals suggest caution. Key risks include integration challenges with Qorvo and ongoing margin pressure, while the RSI near 18 indicates potential oversold conditions for tactical opportunities.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
